Skip to main content
SpringerLink
Log in

Entwicklungspsychopharmakologie

  • Chapter
  • First Online:
Neuro-/Psychopharmaka im Kindes- und Jugendalter

  • 1310 Accesses

Zusammenfassung

Die Entwicklungspsychopharmakologie umfasst alle Fragestellungen der Anwendung von Neuro‑/Psychopharmaka einschließlich der Arzneimittelsicherheit und der Rahmenbedingungen bei einer medikamentösen Behandlung im Kindes- und Jugendalter. In diesem Kapitel werden die Einflüsse der alters- und geschlechtsabhängigen körperlichen und geistigen Reifung auf die Wirkung von Neuro‑/ Psychopharmaka besprochen, und das therapeutische Drug-Monitoring zur Optimierung des Therapieeffektes und als proaktives Instrument zur Förderung der Pharmakovigilanz wird erläutert.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 149.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Aichhorn W, Marksteiner J, Walch T et al. (2007) Age and gender effects of olanzapine and risperidone plasma concentrations in children and adolescents. J Child Adol Psychopharm 17:665–673

    Article  Google Scholar 

  • Andersen SL (2005) Stimulants and the developing brain. Trends Pharmcol Sci 26:237–243

    Article  CAS  Google Scholar 

  • Bai Y, Liu T, Xu A, Yang H, Gao K (2019) Comparison of common side effects from mood stabilizers and antipsychotics between pediatric and adult patients with bipolar disorder: a systematic review of randomized, double-blind, placebo-controlled trials. Exp Opin Drug Saf 18:703–717

    Article  Google Scholar 

  • Correll CU, Carlson HE (2006) Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 45:771–791

    Article  PubMed  Google Scholar 

  • De Hert M, Dobbelaere M, Sheridan EM et al. (2011) Metabolic and endocrine adverse effects of second generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry 26:144–158

    Article  PubMed  Google Scholar 

  • Dragioti E, Solmi M, Favaro A et al. (2019) Association of antidepressant use with adverse health outcomes: a systematic umbrella review. JAMA Psychiatry 76:1241–1255

    Article  PubMed  PubMed Central  Google Scholar 

  • Duijnhoven RG, Straus SM, Raine JM et al. (2013) Number of patients studied prior to approval of new medicines: a database analysis. PLoS Med 10(3):e1001407

    Article  PubMed  PubMed Central  Google Scholar 

  • Egberts K, Mehler-Wex C, Gerlach M (2011) Therapeutic drug monitoring in child and adolescent psychiatry. Pharmacopsychiatry 44:249–253

    Article  CAS  PubMed  Google Scholar 

  • Egberts K, Karwautz A, Plener PL et al. (2015) Pharmakovigilanz in der Kinder- und Jugendpsychiatrie. Z Kinder Jugendpsychiatr 43:21–28

    Article  Google Scholar 

  • Egberts K, Plener P, Malzhan U et al. (2020) Sicherheit von Psychopharmaka bei Kindern und Jugendlichen in der klinischen Praxis – Erkenntnisse einer prospektiven Studie. Bull Arzneimittelsicherh 3:4–10

    Google Scholar 

  • Egberts K, Fekete S, Taurines R et al. (2022a) Therapeutisches Drug Monitoring zur Optimierung der Psychopharmakotherapie von Kindern und Jugendlichen – Update und Leitfaden für die Praxis. Z Kinder Jugendpsychiatrie 50:133. https://doi.org/10.1024/1422-4917/a000845

    Article  Google Scholar 

  • Egberts K, Gerlach M, Correl C et al. (2022b) Serious adverse drug reactions in children and adolescents treated on- and off-label with antidepressants and antipsychotics in clinical practice. Pharmacopsychiatry 55:255. https://doi.org/10.1055/a-1716-1856

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fedorow H, Halliday GM, Rickert CH et al. (2006) Evidence for specific phases in the development of human neuromelanin. Neurobiol Aging 27:506–512

    Article  CAS  PubMed  Google Scholar 

  • Findling RL, Kauffman RE, Sallee FR et al. (2008) Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders. An open-label, dose-escalation study. J Clin Psychopharmacol 28:441–446

    Article  CAS  PubMed  Google Scholar 

  • Findling RL, Kauffman R, Sallee FR et al. (2009) An open-label study of aripiprazole. Pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder. J Child Adolesc Psychopharmacol 19:431–439

    Article  PubMed  Google Scholar 

  • Fornaro M, Anastasia A, Valchera A et al. (2019) The FDA „Black Box“ warning on antidepressant suicide risk in young adults: more harm than benefits? Front Psychiatry 10:294

    Article  PubMed  PubMed Central  Google Scholar 

  • Franke C, Fegert JM, Krüger U, Kölch M (2016) Verordnungshäufigkeiten von Psychopharmaka bei Kindern und Jugendlichen mit psychischen Erkrankungen in Deutschland. Z Kinder Jugendpsychiatr Psychother 44:259–274

    Article  PubMed  Google Scholar 

  • Gerlach M, Wewetzer C (2008) Entwicklungspsychopharmakologie. In: Herpertz-Dahlmann B, Resch F, Schulte-Markwort M, Warnke A (Hrsg) Entwicklungspsychiatrie. Biopsychologische Grundlagen und die Entwicklung psychischer Störungen, 2. Aufl. Schattauer, Stuttgart, S 372–407

    Google Scholar 

  • Gerlach M, Warnke A (2016) Editorial. Medikamentöse Behandlung in der Kinder- und Jugendpsychiatrie in Deutschland zwischen ethischen, sozial- und haftungsrechtlichen Konflikten. Z Kinder Jugendpsychiatr Psychother 44:249–255

    Article  PubMed  Google Scholar 

  • Gerlach M, Egberts K, Dang S-Y et al. (2016) Therapeutic drug monitoring as a measure of proactive pharmacovigilance in child and adolescent psychiatry. Exp Opin Drug Saf 15:1477–1482

    Article  CAS  Google Scholar 

  • Gerlach M, Renner T, Romanos M (2023) Besonderheiten und Probleme der Psychopharmakologie im Kindes- und Jugendalter. Bundesgesundheitsblatt https://doi.org/10.1007/s00103-023-03718-z

  • Giedd JN, Vaituzis C, Hamburger SD et al. (1996) Quantitative MRI of the temporale lobe, amgydala, and hippocampus in normal human development: Ages 4–18 years. J Comp Neurol 366:223–230

    Article  CAS  PubMed  Google Scholar 

  • Giedd JN, Blumenthal J, Jeffries NO et al. (1999) Brain development during childhood and adolescence: a longitudenal MRI study. Nat Neurosci 2:861–863

    Article  CAS  PubMed  Google Scholar 

  • Häge A, Weymann L, Bliznak L et al. (2018) Non-adherence to psychotropic medication among adolescents – A systematic review of the literature. Z Kinder Jugendpsychiatr Psychother 46:69–78

    Article  PubMed  Google Scholar 

  • Hiemke C, Bergemann N, Clement HW et al. (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology – Update 2017. Pharmacopsychiatry 51:9–62

    Article  CAS  PubMed  Google Scholar 

  • Huttenlocher PR (1990) Morphometric study of human cerebral cortex development. Neuropsychologia 28:517–527

    Article  CAS  PubMed  Google Scholar 

  • Karwautz A, Bangratz S, Huemer J (2011) Qualitätssicherung in der kinder- und jugendpsychiatrischen Psychopharmakotherapie – Einsatz von Therapeutic Drug Monitoring. Paediatr Paedolog 2:10–12

    Article  Google Scholar 

  • Kearns GL, Abdel-Rahman SM, Alander SW et al. (2003) Developmental pharmacology – drug disposition, action, and therapy in infants and children. N Engl J Med 349:1157–1167

    Article  CAS  PubMed  Google Scholar 

  • Kloosterboer SM, Vierhout D, Stojanova J et al. (2020) Psychotropic drug concentrations and clinical outcomes in children and adolescents: a systematic review. Exp Opin Drug Saf. https://doi.org/10.1080/14740338.2020.1770224

    Article  Google Scholar 

  • Konradi Ch, Kornhuber J, Sofic E et al. (1992) Variations of monoamines and their metabolites in the human putamen. Brain Res 579:285–290

    Article  CAS  PubMed  Google Scholar 

  • Kornhuber J, Konradi Ch, Mack-Burkhardt F et al. (1989) Ontogenesis of monoamine oxidase-A and -B in the human brain frontal cortex. Brain Res 499:81–86

    Article  CAS  PubMed  Google Scholar 

  • Kryzhanovskaya LA, Xu W, Millen BA et al. (2012) Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine. J Child Adolesc Psychopharmacol 22:157–165

    Article  CAS  PubMed  Google Scholar 

  • Lasser KE, Allen PD, Woolhandler SJ et al. (2002) Timing of new black box warnings and withdrawals for prescription medications. JAMA 287:2215–2220

    Article  PubMed  Google Scholar 

  • Lehmkuhl G, Schubert I (2014) Psychotropic medication in children and adolescents. Dtsch Arztebl Int 111:23–24

    PubMed  PubMed Central  Google Scholar 

  • Morselli PL, Cuche H, Zarifian E (1978) Pharmacokinetics of psychotropic drugs in the pediatric patient. In: Mendlewicz J, van Praag HM (Hrsg) Childhood psychopharmacology: Current concepts. Advances in Biological Psychiatry. Karger, Basel, S 70–86

    Google Scholar 

  • Patel MX, Bowskill S, Couchman L et al. (2011) Plasma olanzapine in relation to prescribed dose and other factors. Data from a therapeutic drug monitoring service, 1999–2009. J Clin Psychopharmacol 31:411–417

    Article  CAS  PubMed  Google Scholar 

  • Paulzen M, Liebe C, Gründer G (2021) Labormonitoring vor und während Psychopharmakotherapie – Schritt für Schritt. PSYCHup2date 15:187–196

    Google Scholar 

  • Smogur M, Onesanu A, Plessen KJ, Eap CB, Anermot N (2022) Psychotropic drug prescription in children and adolescents: approved medications in European countries and the United States. J Child Adol Psychopharmacol. https://doi.org/10.1089/cap.2021.0027

    Article  Google Scholar 

  • Retz W, Kornhuber J, Riederer P (1996) Neurotransmission and the ontology of human brain. J Neural Transm 103:403–419

    Article  CAS  PubMed  Google Scholar 

  • Rivera-Calimlin L, Griesbach PH, Perlmutter R (1979) Plasma chlorpromazine concentrations in children with behavioral disorders and mental illness. Clin Pharmacol Ther 26:114–121

    Article  Google Scholar 

  • Rogers AS (1994) A research agenda for the study of therapeutic agents in adolescents. J Adolesc Health 15:672–678

    Article  CAS  PubMed  Google Scholar 

  • Sammons HM, Gray C, Hudson H, Cherrill J, Choonara I (2008) Safety in paediatric clinical trial – a 7-year review. Acta Paediatr 97:474–477

    Article  CAS  PubMed  Google Scholar 

  • Seeman P, Bzowej NH, Guan H-C et al. (1987) Human-brain dopamine-receptors in children and aging adults. Synapse 1:399–404

    Article  CAS  PubMed  Google Scholar 

  • Taurines R, Burger R, Wewetzer Ch et al. (2013) The relation between dosage, serum concentrations and clinical outcome in children and adolescents treated with sertraline: a naturalistic study. Ther Drug Monit 35:84–91

    Article  CAS  PubMed  Google Scholar 

  • Tini E, Smigielski L, Romanos M et al. (2021) Therapeutic drug monitoring of sertraline in children and adolescents: a naturalistic study with insights into the clinical response and treatment of obsessive-compulsive disorder. Compreh Psychiatry. https://doi.org/10.1016/j.comppsych.2022.152301

    Article  Google Scholar 

  • Thompson PM, Gieddi JN, Woods RP et al. (2000) Growth patterns in the developing brain detected by using continuum mechanical tensor maps. Nature 404:190–193

    Article  CAS  PubMed  Google Scholar 

  • Zito JM, Derivan AT, Kratochvil C et al. (2008) Off-label psychopharmacologic prescribing for children: history supports close clinical monitoring. Child Adolesc Psychiatry Ment Health 2:24

    Article  PubMed  PubMed Central  Google Scholar 

Quellen und weiterführende Literatur

  • Egberts K, Fekete S, Häge A et al. (2022) Therapeutisches Drug Monitoring in der Kinder- und Jugendpsychiatrie – Update und Leitfaden für die Praxis. Z Kinder-jugendpsychiatr Psychother. https://doi.org/10.1024/1422-4917/a000845

    Article  Google Scholar 

  • Gerlach M, Egberts K, Dang S-Y et al. (2016) Therapeutic drug monitoring as a measure of proactive pharmacovigilance in child and adolescent psychiatry. Exp Opin Drug Saf 15:1477–1482

    Article  CAS  Google Scholar 

  • Hiemke C, Bergemann N, Clement HW et al. (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology – Update 2017. Pharmacopsychiatry 51:9–62

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hammelburg, Deutschland

    Prof. Dr. rer. nat. Manfred Gerlach

  2. Zentrum für Psychische Gesundheit, Universitätsklinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Würzburg, Deutschland

    Dr. med. Karin Egberts

  3. Zentrum für Psychische Gesundheit, Universitätsklinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Würzburg, Deutschland

    Priv.-Doz. Dr. med. Regina Taurines

  4. Privatklinik für Seelische Gesundheit, Jugendliche und junge Erwachsene, HEMERA Klinik, Bad Kissingen, Deutschland

    Prof. Dr. med. Claudia Mehler-Wex

Authors
  1. Prof. Dr. rer. nat. Manfred Gerlach
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. med. Karin Egberts
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Priv.-Doz. Dr. med. Regina Taurines
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Prof. Dr. med. Claudia Mehler-Wex
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manfred Gerlach .

Editor information

Editors and Affiliations

  1. Hammelburg, Deutschland

    Manfred Gerlach

  2. Privatklinik für Seelische Gesundheit, Jugendliche und junge Erwachsene, HEMERA Klinik, Bad Kissingen, Deutschland

    Claudia Mehler-Wex

  3. Zentrum für Psychische Gesundheit, Universitätsklinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Würzburg, Deutschland

    Marcel Romanos

  4. Klinik für Kinder- und Jugendpsychiatrie und Psychotherapie, Psychiatrische Universitätsklinik Zürich, Zürich, Schweiz

    Susanne Walitza

  5. KIRINUS Tagesklinik Nymphenburg, München, Deutschland

    Christoph Wewetzer

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Der/die Autor(en), exklusiv lizenziert an Springer-Verlag GmbH, DE, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gerlach, M., Egberts, K., Taurines, R., Mehler-Wex, C. (2023). Entwicklungspsychopharmakologie. In: Gerlach, M., Mehler-Wex, C., Romanos, M., Walitza, S., Wewetzer, C. (eds) Neuro-/Psychopharmaka im Kindes- und Jugendalter. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-65267-1_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-65267-1_2

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-65266-4

  • Online ISBN: 978-3-662-65267-1

  • eBook Packages: Psychology (German Language)

Publish with us

Policies and ethics

Search

Navigation